Zytiga News

Zytiga Q&A

ZYTIGA SUMMARY

Abiraterone acetate, the active ingredient of ZYTIGA is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17alpha±-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.

ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.

Clinical Trials Related to Zytiga (Abiraterone)

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate [Recruiting]
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with
Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with
abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same
doses of abiraterone and steroids they were receiving prior to study entry and will be
randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with
abiraterone. Once the best regimen is established in Part A, based on safety and antitumor
activity, patients will be randomized to the selected treatment regimen and dose of AT13387
in combination with abiraterone or AT13387 alone in Part B (Phase 2).

Pharmacodynamic Study of Abiraterone in the Treatment of Advanced Prostate Cancer [Not yet recruiting]
The purpose of this study is to evaluate the molecular effects of Abiraterone acetate and
prednisone on prostate cancer. Participants will take Abiraterone acetate plus prednisone.
While taking these drugs, patients will undergo sampling of cancer: one before treatment and
one during treatment. To measure the body's overall response to Abiraterone acetate, the
study follows patients for Prostate Specific Antigen (PSA) levels, cancer symptoms, and any
side effects.

- Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with

a standard dose of abiraterone acetate and prednisone by administering different doses
of BEZ235. This will help to find out what effects, good and/or bad, this combination
has on CRPC.

- Phase 2: This part of the study will measure the treatment effect of the combination of

BEZ235 and abiraterone acetate/prednisone on CRPC.

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Recruiting]
This phase II trial studies how well giving abiraterone acetate and prednisone with or
without dasatinib works in treating patients with metastatic, hormone-resistant prostate
cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as abiraterone acetate, may lessen the amount of androgens made by the body. Dasatinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is
not yet known whether abiraterone acetate and prednisone is more effective than abiraterone
acetate, prednisone, and dasatinib in treating prostate cancer